Greenwich LifeSciences (GLSI) News Today $11.95 -0.09 (-0.75%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$11.79 -0.16 (-1.34%) As of 02/21/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Significant Growth in Short InterestGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 644,000 shares, an increase of 5.1% from the January 15th total of 612,700 shares. Based on an average trading volume of 33,700 shares, the short-interest ratio is currently 19.1 days. Currently, 10.9% of the shares of the stock are sold short.February 19 at 7:43 AM | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest UpdateGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 644,000 shares, an increase of 5.1% from the January 15th total of 612,700 shares. Currently, 10.9% of the shares of the company are sold short. Based on an average daily trading volume, of 33,700 shares, the short-interest ratio is presently 19.1 days.February 18, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for GLSI FY2024 Earnings?February 16, 2025 | americanbankingnews.comFY2024 Earnings Estimate for GLSI Issued By HC WainwrightGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Greenwich LifeSciences in a report released on Tuesday, February 11th. HC Wainwright analyst Y. Chen now expects that the company will post earningFebruary 15, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Greenwich LifeSciences (NASDAQ:GLSI)February 13, 2025 | americanbankingnews.comGreenwich LifeSciences (NASDAQ:GLSI) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research report on Tuesday.February 11, 2025 | marketbeat.comGreenwich LifeSciences reports progress in FLAMINGO-01 trialFebruary 10, 2025 | msn.comGreenwich LifeSciences provides update on FLAMINGO-01 open label HLA dataFebruary 10, 2025 | markets.businessinsider.comGreenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01February 10, 2025 | globenewswire.comGreenwich LifeSciences: Long Time To Results, Little Cash, Hard To RecommendFebruary 8, 2025 | seekingalpha.comEMA approves addition of sites to Greenwich LifeSciences’ breast cancer trialJanuary 30, 2025 | finance.yahoo.comGreenwich LifeSciences expands FLAMINGO-01 clinical trial into EuropeJanuary 29, 2025 | markets.businessinsider.comGreenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in EuropeJanuary 29, 2025 | globenewswire.comGreenwich LifeSciences announces activation of Phase 3 trial in PolandJanuary 27, 2025 | markets.businessinsider.comGreenwich LifeSciences Announces Activation of Flamingo-01 in PolandJanuary 27, 2025 | globenewswire.comGreenwich LifeSciences Adds Harvard And Johns Hopkins To FLAMINGO-01January 23, 2025 | markets.businessinsider.comGreenwich LifeSciences provides update on commercial manufacturing of GP2January 23, 2025 | markets.businessinsider.comGreenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01January 23, 2025 | globenewswire.comGreenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update on Commercial ManufacturingJanuary 22, 2025 | finanznachrichten.deGreenwich LifeSciences gains after GP2 commercial manufacturing updateJanuary 22, 2025 | msn.comGreenwich LifeSciences Provides Update on Commercial ManufacturingJanuary 22, 2025 | globenewswire.comGlancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)January 17, 2025 | businesswire.comGreenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01January 14, 2025 | globenewswire.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 2,500 Shares of StockJanuary 14, 2025 | insidertrades.comGreenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into FranceJanuary 13, 2025 | markets.businessinsider.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys 2,500 Shares of StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 2,500 shares of the stock in a transaction dated Friday, January 10th. The shares were purchased at an average price of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the purchase, the chief executive officer now directly owns 5,552,502 shares in the company, valued at $69,461,800.02. The trade was a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.January 13, 2025 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 1,800 SharesJanuary 9, 2025 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 1,800 SharesGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 1,800 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The stock was purchased at an average cost of $13.75 per share, for a total transaction of $24,750.00. Following the transaction, the chief executive officer now owns 5,550,002 shares in the company, valued at $76,312,527.50. The trade was a 0.03 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.January 8, 2025 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 2,000 SharesJanuary 7, 2025 | insidertrades.comSnehal Patel Buys 2,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock in a transaction on Thursday, January 2nd. The stock was acquired at an average price of $11.97 per share, for a total transaction of $23,940.00. Following the purchase, the chief executive officer now owns 5,543,702 shares of the company's stock, valued at approximately $66,358,112.94. This trade represents a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.January 6, 2025 | marketbeat.comSnehal Patel Acquires 3,200 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockJanuary 3, 2025 | insidertrades.comSnehal Patel Buys 3,200 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average cost of $11.12 per share, for a total transaction of $35,584.00. Following the purchase, the chief executive officer now directly owns 5,539,302 shares in the company, valued at $61,597,038.24. The trade was a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 2, 2025 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Up 8.1% in DecemberGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 530,200 shares, a growth of 8.1% from the November 30th total of 490,400 shares. Approximately 9.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 28,200 shares, the short-interest ratio is presently 18.8 days.January 1, 2025 | marketbeat.comGreenwich LifeSciences Partners With Breast C...November 26, 2024 | benzinga.comGreenwich LifeSciences Partners with GIM in ItalyNovember 26, 2024 | globenewswire.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Buys $12,910.00 in StockNovember 26, 2024 | insidertrades.comJaye Thompson Acquires 1,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) VP Jaye Thompson purchased 1,000 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The shares were purchased at an average price of $12.91 per share, for a total transaction of $12,910.00. Following the completion of the acquisition, the vice president now directly owns 264,148 shares in the company, valued at $3,410,150.68. The trade was a 0.38 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.November 25, 2024 | marketbeat.comGreenwich LifeSciences Provides Update on Corporate EventsNovember 18, 2024 | globenewswire.comGreenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 1.6% - Time to Sell?Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 1.6% - Should You Sell?November 14, 2024 | marketbeat.comGreenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 3.1% - Still a Buy?Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 3.1% - Still a Buy?October 23, 2024 | marketbeat.comGreenwich LifeSciences (NASDAQ:GLSI) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comInsider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 1,500 Shares of StockOctober 1, 2024 | insidertrades.comSnehal Patel Acquires 1,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 1,500 shares of the firm's stock in a transaction on Thursday, September 26th. The stock was acquired at an average price of $14.63 per share, for a total transaction of $21,945.00. Following the completion of the transaction, the chief executive officer now directly owns 5,536,102 shares of the company's stock, valued at approximately $80,993,172.26. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.September 30, 2024 | marketbeat.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Buys 800 SharesSeptember 17, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders seem bullish, own 55% and have been buying more recentlySeptember 12, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$3.36m On Greenwich LifeSciencesAugust 17, 2024 | uk.finance.yahoo.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $72,490.00 in StockAugust 8, 2024 | insidertrades.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 5,500 SharesGreenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 5,500 shares of the stock in a transaction on Monday, August 5th. The shares were acquired at an average cost of $13.18 per share, with a total value of $72,490.00. Following the acquisition, the chief executive officer now directly owns 5,532,602 shares in the company, valued at approximately $72,919,694.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.August 7, 2024 | marketbeat.comJaye Thompson Purchases 1,000 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) StockAugust 6, 2024 | insidertrades.comGreenwich Lifesciences Inc (GLSI)August 4, 2024 | investing.com Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address GLSI Media Mentions By Week GLSI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLSI News Sentiment▼1.210.60▲Average Medical News Sentiment GLSI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLSI Articles This Week▼61▲GLSI Articles Average Week Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANAB News Today KURA News Today CRMD News Today ABUS News Today PHAR News Today IMTX News Today ORIC News Today RAPP News Today SEPN News Today PGEN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLSI) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.